2027 ICD-10-CM Diagnosis Code T38.3X5AAdverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter

ICD-10-CM Codes›S00–T88›T36-T50›T38

ICD-10-CM T38.3X5A
CMSSource: CMS FY 2027 ICD-10-CM dataset · Effective Oct 1, 2026 – Sep 30, 2027

T38.3X5A is a billable ICD-10-CM diagnosis code for adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 791, 793, 917 through 918. The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Adverse effects of drugs and medicaments, initial encounter.

Code Identity

ICD-10-CM Code
T38.3X5A
Billable Status
Yes — Valid for Submission
Code Describes
Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter
Short Description
Adverse effect of insulin and oral hypoglycemic drugs, init
Parent Code
Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT38Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified
This CodeT38.3X5AAdverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter

Code EditsBilling

Medicare Code Editor checks that affect claim validity for T38.3X5A.

There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Acarbose adverse reaction
  • Acetohexamide adverse reaction
  • Adverse reaction caused by human insulin
  • Adverse reaction following injection of substance
  • Adverse reaction to biguanide hypoglycemic agent
  • Adverse reaction to sulfonyluric hypoglycemic
  • Adverse reaction to zinc insulin
  • Biguanide adverse reaction
  • Chlorpropamide adverse reaction
  • Diabetic drug side effects
  • Drug-induced anaphylaxis
  • Fat hypertrophy
  • Glibenclamide adverse reaction
  • Glibornuride adverse reaction
  • Gliclazide adverse reaction
  • Glipizide adverse reaction
  • Gliquidone adverse reaction
  • Glucagon adverse reaction
  • Glymidine adverse reaction
  • Insulin adverse reaction
  • Insulin lipoatrophy
  • Insulin lipohypertrophy
  • Insulin-induced anaphylaxis
  • Isophane insulin adverse reaction
  • Lipoatrophy caused by injected drug
  • Localized lipoatrophy
  • Metformin adverse reaction
  • Pancytopenia caused by antidiabetic drug
  • Pancytopenia caused by medication
  • Protamine zinc insulin adverse reaction
  • Regular insulin adverse reaction
  • Sulfonylurea adverse reaction
  • Tolazamide adverse reaction
  • Tolbutamide adverse reaction

Coding GuidelinesGuidance

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified (T38). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2027, published by CMS and the National Center for Health Statistics.

Instructional NotesGuidance

Instructions from the official ICD-10-CM Tabular List that apply to T38.3X5A: its own notes plus those printed at T38, block T36-T50, and Chapter 19. A note printed at a category, block or chapter applies to every code under it.

Includes

Further defines, or gives examples of, the content of the category.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • adverse effect of correct substance properly administered
  • poisoning by overdose of substance
  • poisoning by wrong substance given or taken in error
  • underdosing by (inadvertently) (deliberately) taking less substance than prescribed or instructed

Excludes1

Not coded here: the excluded code is never reported together with this one, unless the two conditions are unrelated.

From T38 Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified applies to 234 codes
  • mineralocorticoids and their antagonists (T50.0-)
  • oxytocic hormones (T48.0-)
  • parathyroid hormones and derivatives (T50.9-)
From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • toxic reaction to local anesthesia in pregnancy (O29.3-)

Excludes2

Not included here: the excluded condition is not part of this code, but a patient may have both, so both codes may be reported.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • abuse and dependence of psychoactive substances (F10-F19)
  • abuse of non-dependence-producing substances (F55.-)
  • immunodeficiency due to drugs (D84.821)
  • drug reaction and poisoning affecting newborn (P00-P96)
  • pathological drug intoxication (inebriation) (F10-F19)
From Chapter 19 (S00-T88) Injury, poisoning and certain other consequences of external causes applies to 41,187 codes

Code First

The underlying condition named in the note is sequenced before this code.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • for adverse effects, the nature of the adverse effect, such as:
  • adverse effect NOS (T88.7)
  • aspirin gastritis (K29.-)
  • blood disorders (D56-D76)
  • contact dermatitis (L23-L25)
  • dermatitis due to substances taken internally (L27.-)
  • nephropathy (N14.0-N14.2)

Use Additional Code

Add a second code, after this one, to fully describe the condition.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • code(s) to specify:
  • manifestations of poisoning
  • underdosing or failure in dosage during medical and surgical care (Y63.6, Y63.8-Y63.9)
  • underdosing of medication regimen (Z91.12-, Z91.13-)
From Chapter 19 (S00-T88) Injury, poisoning and certain other consequences of external causes applies to 41,187 codes
  • code to identify any retained foreign body, if applicable (Z18.-)

Notes

General instructions on how these codes are used.

From Block T36-T50 Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances applies to 3,186 codes
  • The drug giving rise to the adverse effect should be identified by use of codes from categories T36-T50 with fifth or sixth character 5.
From Chapter 19 (S00-T88) Injury, poisoning and certain other consequences of external causes applies to 41,187 codes
  • Use secondary code(s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code
  • The chapter uses the S-section for coding different types of injuries related to single body regions and the T-section to cover injuries to unspecified body regions as well as poisoning and certain other consequences of external causes.

7th Character

Every code in the category takes a 7th character from the listed values, with the placeholder X filling any empty positions before it.

From T38 Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified applies to 234 codes
  • The appropriate 7th character is to be added to each code from category T38
  • Ainitial encounter this code
  • Dsubsequent encounter
  • Ssequela

Source: CMS ICD-10-CM Tabular List. How to read instructional notes.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR INJ028
Adverse effects of drugs and medicaments, initial encounter
Default principal diagnosis: inpatient No · outpatient Yes

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect
Under­dosing
AcetohexamideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Antidiabetic NECT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Antidiabetic NEC::biguanideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Antidiabetic NEC::biguanide::and sulfonyl combinedT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Antidiabetic NEC::combinedT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Antidiabetic NEC::sulfonylureaT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Biguanide derivatives, oralT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
BuforminT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
CarbutamideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
ChlorpropamideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
DBIT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
DiabineseT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Dimethyl::diguanideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
DymelorT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Extended insulin zinc suspensionT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlibenclamideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlibornurideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GliclazideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlimidineT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlipizideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GliquidoneT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlisolamideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlisoxepideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Globin zinc insulinT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlucagonT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlyburideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlyclopyramideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
GlycyclamideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Glymidine sodiumT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Hormone::antidiabetic agentsT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
IletinT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insular tissue extractT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)T38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)::defalanT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)::humanT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)::injection, solubleT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)::injection, soluble::biphasicT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)::intermediate actingT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)::protamine zincT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)::slow actingT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)::zinc::protamine injectionT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Insulin (amorphous) (globin) (isophane) (Lente) (NPH) (Semilente) (Ultralente)::zinc::suspension (amorphous) (crystalline)T38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Isophane insulinT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Lente Iletin (insulin)T38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
MetforminT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Neutral insulin injectionT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
NPH Iletin (insulin)T38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
OrinaseT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
PhenforminT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
PhenylethylbiguanideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Protamine sulfate::zinc insulinT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
PZIT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Sodium::tolbutamideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Sulfonylurea derivatives, oralT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
TolazamideT38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6
Tolbutamide (sodium)T38.3X1T38.3X2T38.3X3T38.3X4T38.3X5T38.3X6

Patient EducationClinical

Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

The full article covers:

  • What is a drug interaction?
  • What are side effects?
  • What are drug allergies?
  • How can I stay safe when taking medicines?

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T38.3X5A to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
995.23 Adverse eff insulin NOS
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E932.3 Adv eff insulin/antidiab
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2026No changes
FY 2027CurrentCurrent code set, no changesEffective October 1, 2026 through September 30, 2027.

Questions About T38.3X5AOverview

Is T38.3X5A a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter on HIPAA-covered claims from October 1, 2026 through September 30, 2027.

What does the 7th character A in T38.3X5A mean?

The final character A marks the initial encounter: use it while the patient is receiving active treatment for adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, such as an emergency visit or first evaluation.

What MS-DRG does T38.3X5A group to?

On inpatient claims, adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter maps to MS-DRG 793, 791, 918, 917, with relative weights from 0.8716 to 4.2192 depending on complications. Higher weights mean higher Medicare reimbursement.

Can T38.3X5A be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Can T38.3X5A be reported with a code from T50.0?

Not as a rule. The Excludes1 note at T38, which applies to T38.3X5A, lists "mineralocorticoids and their antagonists (T50.0-)". An Excludes1 note means the excluded code is never reported together with this one; the only exception is when the two conditions are unrelated to each other (Official Guidelines, Section I.A.12.a).